Catalyst overview
Research summary
This catalyst tracks a Phase 2 data readout for Empasiprubart in Delayed graft function. The expected timing is based on the latest available company guidance and may change.
Initiation by YE 2023. 01/12/26:- VARVARA Phase 2 DGF study decision after 52-week efficacy analysis by Mid-2026.
Verification
Confirm timing and program details against the company announcement or filing.